KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Total Liabilities for 7 consecutive years, with $9.9 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 25.7% to $9.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 billion through Dec 2025, up 25.7% year-over-year, with the annual reading at $9.9 billion for FY2025, 25.7% up from the prior year.
  • Total Liabilities hit $9.9 billion in Q4 2025 for Royalty Pharma, up from $9.7 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $9.9 billion in Q4 2025 to a low of $6.1 billion in Q1 2021.
  • Historically, Total Liabilities has averaged $7.5 billion across 5 years, with a median of $7.3 billion in 2022.
  • Biggest five-year swings in Total Liabilities: surged 184.84% in 2021 and later decreased 13.59% in 2023.
  • Year by year, Total Liabilities stood at $7.3 billion in 2021, then grew by 0.29% to $7.3 billion in 2022, then fell by 13.59% to $6.3 billion in 2023, then increased by 25.13% to $7.9 billion in 2024, then increased by 25.7% to $9.9 billion in 2025.
  • Business Quant data shows Total Liabilities for RPRX at $9.9 billion in Q4 2025, $9.7 billion in Q3 2025, and $8.8 billion in Q2 2025.